What Is Ozempic Face and How Can Aesthetic Practitioners Treat It?

If you have been seeing more patients recently who look noticeably older than their age, despite being in better physical shape than ever, there is a good chance you are already seeing the effects of Ozempic face

Millions of people across the UK and worldwide are now taking GLP-1 receptor agonist medications like Ozempic, Wegovy, and Mounjaro for weight loss. Many of them are getting excellent results on the scales. But a growing number are walking into aesthetic clinics with hollow temples, sunken cheeks, and a general gauntness that was not there before.

This is what the aesthetic world is calling Ozempic face. And for practitioners who understand what is happening and know how to treat it, this represents one of the most significant clinical and commercial opportunities in aesthetics right now.

In this guide, we walk through exactly what Ozempic face is, why it happens, how to assess it at consultation, and what the most effective treatment approaches look like in 2026. Whether you are already seeing these patients or preparing to, this is everything you need to know. 

Ozempic face is the term used to describe the facial volume loss and premature ageing appearance that can occur following rapid, significant weight loss, particularly in patients using GLP-1 receptor agonist medications such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound).

The term was first coined in 2023 by American dermatologist Dr Paul Jarrod Frank. It has since become one of the most searched health and aesthetics terms globally, with search interest rising dramatically in the years since GLP-1 medications became widely prescribed. 

It is worth noting that Ozempic face is not a formal medical diagnosis. It is a descriptive term for a collection of facial changes that can result from any form of rapid, substantial weight loss, not just weight loss caused by medication. 

It is also important to say upfront: many patients experience significant health benefits and improved quality of life from GLP-1 medications. The facial changes discussed in this guide are aesthetic rather than medically harmful, and they are manageable with the right approach. 

The classic presentation of Ozempic face includes: 

• Hollow or sunken templ
• Flattened or deflated-looking cheeks
• Deepened nasolabial folds (smile lines
• Increased hollowing under the eyes (tear troughs)
• Jowl formation or softening of the jawline
• Increased skin laxity around the lower face and neck
• An overall gaunt or tired appearance

These changes tend to make patients look older than their actual age. Observational studies and blinded assessments suggest that significant weight los

To understand Ozempic face, you need to understand the role that facial fat plays in maintaining a youthful appearance. 

The face contains multiple distinct fat compartments, both superficial and deep. These fat pads sit beneath the skin and act as structural support, providing volume, projection, and smooth contours. When we lose weight, those fat pads shrink. And when that happens quickly, the overlying skin simply does not have enough time to adapt. 

Gradual weight loss over months or years allows the skin's natural collagen remodelling cycles to partially compensate for decreasing volume. Rapid weight loss, driven by GLP-1 medications, can strip away significant facial volume in a matter of weeks. The result is a visible mismatch between the skin envelope and the underlying structure. 

Some research has attempted to quantify the relationship between total weight loss and facial volume change, and findings consistently point to the midface as the most affected region, though individual variation is significant. 

Understanding those fat compartments in depth, including which ones are most vulnerable to GLP-1-related depletion, is exactly the kind of foundation that our online facial anatomy course is built around. 

This is a question researchers are actively exploring. The short answer is: possibly, yes. 

GLP-1 receptors have been identified in skin cells, including fibroblasts, the cells responsible for producing collagen and elastin. Early laboratory research has explored whether GLP-1 signalling may influence fibroblast behaviour and collagen metabolism, although the clinical significance of this remains unclear. What this may mean is that semaglutide face changes are not entirely explained by weight loss alone, but this area of research is still developing. 

There is also evidence that GLP-1-induced weight loss preferentially affects the superficial fat compartments of the face. This distinct pattern of fat loss may be why Ozempic face can look so pronounced, even in younger patients who have only lost a moderate amount of weight. 

Not every patient on a GLP-1 medication will develop noticeable facial changes. But certain factors increase the likelihood and severity. 

The key risk factors for developing Ozempic face include: 

• Large total weight loss. Patients losing more than 20% of their body weight are significantly more at risk.
• Rapid dose escalation. Faster weight loss means less time for skin adaptation.
• Age. Patients over 40 tend to have less skin elasticity and reduced collagen density, making facial changes more visible.
• Existing skin quality. A history of smoking, sun damage, or poor nutrition compounds the effects.
• Low protein intake during weight loss. Inadequate protein accelerates loss of lean tissue and impairs skin quality.
• Naturally thinner skin. Patients with less subcutaneous tissue to begin with will show changes earlier. 

Understanding these risk factors helps at consultation. Patients who tick several of these boxes should be counselled early about the likelihood of facial changes, and a proactive treatment plan should be discussed before changes become severe. 

The consultation process itself is a skill. If you want to strengthen your approach to assessing patients before treatment, our blog on how to assess skin before treatment covers this in practical detail. 

The assessment for Ozempic face follows the same principles as any good facial aesthetic consultation, but with some important additions specific to this patient group. 

Start with a thorough patient history. You need to know: 

• Which GLP-1 medication they are taking 
• How long they have been on it and at what dose 
• How much weight they have lost and over what period 
• Whether they are still actively losing weight 
• What their nutritional intake has been like during the weight loss process

The answer to that last point matters more than many practitioners realise. Patients who have neglected protein intake or become significantly calorie-restricted may have compromised skin quality that will affect how treatments perform. 

This is the most important question you will ask. Weight stabilisation is often more important than immediate volumisation. If the patient is still actively losing weight, starting volumising injectables is generally premature. 

Placing filler into a face that is still changing can lead to asymmetry, an unnatural result, and the need for early revision. In these cases, the better approach is to begin with skin quality treatments first, focusing on laxity, hydration, and collagen stimulation. This prepares the skin for when volumising treatment becomes appropriate. 

It is also worth discussing the possibility of weight regain if the medication is stopped. This can partially reverse facial ageing changes and may affect how previous treatments sit. 

A structured facial assessment for GLP-1 facial volume loss should cover: 

• Temples. Hollow temples are often one of the earliest visible signs of Ozempic face. 
• Midface and cheeks. Has there been a loss of anterior projection or a flattening of the submalar triangle? 
• Under-eyes. How deep are the tear troughs? Infraorbital hollowing is a key feature of semaglutide face. 
• Nasolabial folds. Have the smile lines deepened beyond what would be expected for the patient's age? 
• Jawline and jowls. Is there early jowl formation or softening of jaw definition? 
• Neck and lower face. What is the degree of skin laxity present? 
• Skin quality overall. Is the skin thin, crepey, or dehydrated? 

A 2026 study published in Aesthetic Surgery Journal confirmed that the most pronounced volume losses in GLP-1 patients occur in the medial cheek, sub-orbicularis oculi (under-eye area), and temporal fat pads. These are the regions that deserve the most attention in your assessment. 

There is clear clinical consensus that treating Ozempic face well requires a multimodal approach. No single treatment adequately addresses all of the changes present. The right combination depends on the individual patient: their degree of volume loss, the amount of skin laxity, their age, and their aesthetic goals. 

If you are new to thinking about treatments in a layered, multimodal way, our blog on combination aesthetic treatments is a useful place to start. It covers how to layer Botox, fillers, and biostimulators together safely and effectively. 

Here is a breakdown of the main treatment options available.

Hyaluronic acid (HA) dermal fillers are a cornerstone treatment for GLP-1 facial volume loss. They provide immediate, visible volume restoration in the specific fat compartments most affected by rapid weight loss. 

The priority areas for dermal fillers in Ozempic face patients are: 

• The temples, to restore lateral facial support 
• The cheeks and midface, to rebuild projection and lift 
• The tear troughs, where appropriate and following careful patient assessment 
• The nasolabial folds, where deepening is driven by volume collapse above 

For Ozempic face specifically, the approach should be structural and layered. Working deep first to restore the scaffolding, then refining surface concerns, tends to give the most natural and balanced result. 

It is also worth noting that not every Ozempic face patient is a suitable candidate for dermal fillers. In patients with severe skin laxity or advanced tissue descent, fillers alone may worsen heaviness or produce an unnatural outcome. In these cases, skin tightening treatments or surgical referral may be more appropriate. 

A single aggressive volumising session is rarely appropriate. A staged plan with a review appointment is usually the better approach. If you are earlier in your injectable training, our beginners guide to Botox and dermal filler provides a solid foundation on products, technique, and patient assessment. 

For many Ozempic face patients, biostimulators are the most appropriate starting point. They address the underlying collagen and structural deficit rather than simply adding volume. 

Sculptra (poly-L-lactic acid) stimulates the body's own collagen production, gradually restoring volume over several months. Results from Sculptra for Ozempic face can last 18 to 24 months. When combined with HA fillers, the outcomes are significantly more comprehensive and longer-lasting. 

Clinical experience and published data from biostimulator manufacturers suggest high levels of patient satisfaction when this approach is used for medication-driven facial volume loss, particularly when results are assessed at follow-up rather than immediately after treatment. 

Calcium hydroxylapatite biostimulators such as Radiesse are also useful in this context, offering both immediate volume and collagen stimulation, particularly for the midface and jawline. 

When significant skin laxity is present, as is common after rapid weight loss, injectable treatments alone will not produce the best results. Skin tightening modalities need to be part of the plan. 

Options include: 

• Radiofrequency (RF) treatments, which stimulate collagen and tighten lax tissue. 
• Ultrasound-based skin tightening, which targets deeper structural layers to lift and firm. 
• RF microneedling, which improves skin quality, texture, and laxity. 

Skin tightening treatments work particularly well when scheduled ahead of or alongside injectable volume restoration. 

PDO (polydioxanone) threads can play a useful role in the treatment of Ozempic face, particularly where there is significant jowling or descent of the midface tissues. 

Threads provide mechanical lifting and also stimulate collagen production along the thread pathway. For patients with moderate skin laxity who are not yet candidates for surgical intervention, a well-planned thread lift combined with biostimulators and HA fillers can produce a meaningful improvement. 

For patients with significant volume loss and skin laxity, non-surgical options may not be sufficient. Demand for facial fat grafting has risen considerably in recent years, with many surgical practices attributing a notable proportion of that increase to patients on GLP-1 medications. 

Facelift and neck lift procedures remain the gold standard for advanced facial ageing in this group. Non-surgical practitioners should feel confident referring patients who have progressed beyond what injectables can address, and having a clear referral pathway is part of good patient care. 

Planning treatment for Ozempic face patients requires more thought than a standard filler consultation. The most effective approach is staged, personalised, and responsive to where the patient is in their weight loss journey. 

A typical treatment programme might follow this sequence: 

1. Initial consultation and assessment. Establish weight loss history, current trajectory, medication status, and skin quality. 
2. Skin preparation phase. If the patient is still losing weight, focus on skin quality treatments such as skin boosters, biostimulators, and topical protocols to improve skin condition. 
3. Volume restoration phase. Once weight has stabilised, begin structural volumising with biostimulators first, followed by HA filler placement. 
4. Refinement and maintenance. Review results, address remaining concerns, and schedule maintenance treatments. 

Patients should also be counselled on the importance of nutrition during weight loss. A diet adequate in protein, vitamin C, and essential fatty acids supports skin quality and helps minimise facial ageing changes. Hydration and appropriate skincare, including retinoids and antioxidants, are also worth discussing. 

GLP-1 patients tend to require more frequent review than standard aesthetic patients, particularly in the early stages. Their facial landscape is actively changing, and treatment plans need to be adapted accordingly. 

Setting realistic expectations at the start is essential. Patients should understand that treating Ozempic face is a process, not a one-appointment fix. Practitioners who manage expectations well and deliver staged, visible results will build strong long-term patient relationships in this group. 

Understanding how and when to combine different treatments, and how to sequence them safely, is one of the most valuable clinical skills you can develop. Our detailed guide on combination aesthetic treatments and layering covers exactly this. 

The scale of GLP-1 prescribing has reached a point where no practitioner working in aesthetics can afford to overlook this patient group. 

A November 2025 KFF Health Tracking Poll found that 12% of US adults, roughly 31 million people, are currently taking a GLP-1 drug, up from just 6% in May 2024. In the UK, semaglutide has been available on the NHS for weight loss since 2023. 

Industry surveys of aesthetics providers have consistently found that a meaningful proportion of GLP-1 patients seeking facial treatments are new to cosmetic medicine entirely. This represents a patient group that would not previously have engaged with aesthetic clinics, now arriving with a specific and understandable concern. 

The global obesity medication market is projected to reach $105 billion by 2030. That is not a niche trend. It is a fundamental shift in the patient population that aesthetic practitioners will serve. 

Practitioners who understand how to assess and treat GLP-1 facial changes, who can explain the process clearly and build appropriate treatment plans, are already seeing increased demand. Those who develop genuine expertise in this area now are positioning themselves at the forefront of one of the most significant clinical developments in aesthetics this decade. 

Treating Ozempic face well requires a solid foundation in facial anatomy, a thorough understanding of injectable products and their properties, and confidence in building a multimodal treatment plan. These are not skills that come from a single afternoon workshop. 

For practitioners looking to build or strengthen these skills, structured online aesthetics training is one of the most accessible and effective ways to do so. Our online aesthetics courses are designed specifically for medical professionals, covering: 

• Facial anatomy in depth, including the fat compartments most affected by GLP-1 weight loss 
• Injectable technique for HA fillers and biostimulators 
• Complications management and safety protocols, covered in full in our complications course 
• Patient consultation and treatment planning 
• Advanced techniques including PDO threads and skin tightening 

Online learning in aesthetics allows you to study at your own pace and revisit material as many times as you need to. This is particularly valuable for building the kind of deep anatomical and clinical knowledge that translates into confident, safe practice. 

As GLP-1 patients continue to enter aesthetic clinics in growing numbers, the practitioners who will serve them best are those with a strong, current understanding of facial anatomy, product knowledge, and treatment planning. You can explore our full range of courses and pricing plans to find the option that fits your learning goals. 

Before we close, here is a quick summary of the most important points: 

• Ozempic face refers to the facial volume loss and premature ageing that can follow rapid weight loss, particularly from GLP-1 medications like Ozempic, Wegovy, and Mounjaro. 
• It is caused by the rapid depletion of facial fat pads, which the skin cannot adapt to quickly enough. 
• The most affected areas are the temples, midface, under-eyes, and nasolabial folds. 
• Treatment requires a multimodal approach, typically combining HA dermal fillers, biostimulators such as Sculptra, and skin tightening modalities. 
• Assessment must establish whether the patient is still actively losing weight before any volumising treatment begins. 
• GLP-1 patients represent a large and growing new patient group for aesthetic practitioners. 
• Building the right clinical foundation through structured aesthetics training is essential for treating this group well. 

At DermaHub, we offer online aesthetics courses designed for medical professionals who want to practise with skill, confidence, and clinical accuracy. 

Our eLearning platform covers everything from facial anatomy and injectable technique to advanced treatments and complications management. All content is available on demand, so you can learn around your existing clinical commitments. 

Whether you are just starting out in aesthetics or looking to expand your existing skills to serve patients experiencing Ozempic face and GLP-1-related facial changes, DermaHub has the training to help you get there. 

Explore our courses and pricing plans and take the next step in your aesthetic career today.